key: cord-0881596-t6kgkgdb authors: Clifford, Sean P.; Ramirez, Julio; Akca, Ozan; Ghafghazi, Shahab; Huang, Jiapeng title: Perioperative Cardiac Research Considerations During the COVID-19 Pandemic date: 2021-02-05 journal: J Cardiothorac Vasc Anesth DOI: 10.1053/j.jvca.2021.01.052 sha: b6c883eea9913aeaa848743375c2d2da6c7f25bd doc_id: 881596 cord_uid: t6kgkgdb nan Jiapeng Huang is supported by Gilead Sciences COMMIT COVID-19 RFP Program grant. All authors declared no conflict of interest. Sean P. Clifford , Julio Ramirez, Ozan Akca, Shahab Ghafghazi, Jiapeng Huang: Study design, data analysis, manuscript preparation. The coronavirus disease-2019 (COVID- 19) pandemic has dramatically changed the entire health care delivery system and conduction of medical research worldwide. At the beginning of the pandemic, many trials were forced to close abruptly, experiments were discarded, laboratories were temporarily shut down, and investigators became hesitant to start long term studies due to the fear of potential lockdowns. (1, 2) As of August, 2020, there remained a 20% decline from pre-COVID baseline in new patients entering cardiovascular trials, although this number is significantly improved from the 97% decline as reported in April 2020. trials has undoubtedly resulted in success and is a testament to the worldwide research community, the rushed nature of this research has led to much duplication and production of many poor-quality trials. Most initial COVID-19 clinical trials were openlabel, few were placebo-controlled, results were often preliminary, and at many times published data were not benefitted from peer review. Therefore, significant number of reports have limited use to clinicians or patients as they have frequently led to incorrect conclusions, which were subsequently invalidated by well-designed large randomized controlled trials. (6) Notably, in the rush to disseminate knowledge, prestigious journals such as the New England Journal of Medicine and The Lancet have retracted previously published articles, which were seen as major COVID-findings at the time of publication. (7, 8) A full list of retracted COVID-19 papers can be found at Retraction Watch. (9) Double-blinded, randomized, controlled trials, whether new or repurposed, preferably with a placebo comparator should be designed, even though the pandemic adds challenges to these constructions. Large, long-term trials that establish standards for drug treatments are of such vital importance to the public health that every effort, including investigator blinding, should be built into the trial design to produce valid results in studies of the highest reliability and the clearest interpretation. Research Cost: As a result of COVID-19, researchers may incur unanticipated costs, such as costs to arrange for participants to receive care virtually or at alternative sites, supply chain disruptions, personnel disruptions due to illness or closure of facilities, additional lab testing (e.g. for COVID-19), and increased transportation costs. Renegotiation might be needed with the sponsor to cover these necessary spending. Patient Behavior: Patient behavior has changed markedly due to fears of infection and social distancing mandates by local authorities, leading to decreased medical care and altered nonfatal event rates. For example, the COVID-19 pandemic was temporally associated with a 40% decrease in presentation for acute coronary syndromes. (10, 11) Heart failure hospitalization rates have dropped up to 50% with regional COVID-19 spread and governmental activity restrictions. (12) Selection bias is a significant concern in clinical investigations of patients presenting to surgery as this cohort may not be representative of the general population. In addition to the reduced potential pool for perioperative research, some studies lack feasibility due to patient fears related to travel and social interaction as well as hospital restrictions. Care Personnel: During the pandemic, disease-specific care teams were altered to accommodate the intensity of COVID-19 admissions and care. For example, nationally and internationally, many internists, hospitalists, anesthesiologists, surgeons, and cardiologists joined the COVID-19 care teams to support their colleagues to prevent the overburdens. These efforts likely impacted the regular expert teams' usual access to cardiovascular illnesses and associated events. Additionally, the efforts to decrease trainee burdens may have further challenged the manpower of academic centers' caring for cardiovascular problems properly. Safety: The safety of trial participants and research staff is of paramount importance during COVID-19. Investigators, sponsors, and local institutions need to decide on the safety of continued trial subject recruitment, use of investigational products (nature of disease, supply chain issues, withdrawal risks from investigational treatment), and novel strategies for follow-up visits and patient monitoring methods (phone contact, virtual visit, alternative location for assessment). Research staff/investigators must also follow strict local isolation and social distancing policies to reduce the spread of coronavirus. NIH recommends (5): 6 1). Limiting study visits to those needed for participant safety or coincident with clinical care. 2). Conducting virtual study visits. 3). Arranging flexibilities for required laboratory tests or imaging needed for safety monitoring to occur at local laboratories or clinics. for timed walking tests. (14) However, measurement error, poor device reliability, lack of performance testing, missing data, and the needed patient reminders to wear nonimplantable devices to record activity are limitations which can cause data inaccuracy. Wearable technology could also have psychological consequences that alter behavior, and it is unclear whether data from different modalities can be pooled. Mask-wearing may also effect performance and must be a consideration. In addition, activity data from implantable devices may cause data imbalance between groups as many participants lack these devices. (15) Additionally, interchangeability of these devices or the quality and the compatibility of data driven from different devices are not known at this point. To facilitate analysis, it is best to record the mode of test administration, modifying only as necessary to maximize data collection while maintaining procedural integrity. For example, New York Heart Association (NYHA) functional class may be remotely assessed, but the means of collection should be recorded and its value to clinical trials should continue to be reexamined and compared to data collected in person. infection and associated inflammation might increase risk of thrombosis, heart failure, myocardial infarction, and myocarditis. (16, 18) There remains concern that certain cardiovascular medications may augment COVID-19 infection by aiding the virus in entering the cells via the angiotensin system. (19) However, recent randomized control trial demonstrated that among patients hospitalized with mild to moderate COVID-19 and who were taking angiotension converting enzyme inhibitors or angiotensin II receptor blocker before hospital admission, there was no significant difference in the mean number of days alive and out of the hospital for those assigned to discontinue vs continue these medications. (20) Furthermore, due to the loss of employment from economic lockdown and social restrictions, some patients may be unable to obtain appropriate therapeutics thus leading to new/recurrent cardiovascular events and death. Due to the multi-system impact from COVID-19, renal injury and pulmonary injury are common from COVID-19 and might not be possible to discern from trial related interventions. because infection is associated with increased circulating levels of common indices, and biomarkers denote risk for severe COVID-19 disease and worse outcomes. (16, 18) Although in many cases biomarker changes appear to be due to noncardiac critical illness, this coronavirus appears to have tropism for the myocardium and vasculature. (12) Thus, COVID-19 complicates adjudication of myocardial injury events and worsening cardiovascular events because the symptomatology and biomarkers may be consistent with either COVID-19 or primary cardiovascular conditions. (17) Statistical Analysis: For a trial that has enrolled few patients, sponsors may consider either substantially revising the statistical plan, or designing a new trial to begin after the COVID-19 pandemic has sufficiently waned in order to account for changes/challenges in the current clinical trial environment. Statistically accounting for the timeline and intensity with which COVID-19 affected local or regional clinical care and patient behavior could help adjust for the comprehensive changes in health care utilization and efficacy associated with the COVID-19 pandemic, including increased overall mortality rates, decreased health care utilization, and excess cardiovascular mortality due to COVID-19. Overall, incidences of common medical illnesses, their hospital admission priorities, routine clinic follow up visit practices, and chronic disease admissions are likely changed to a great extent during the lengthy pandemic period. In short, the whole annual statistics for chronic illnesses may have been significantly impacted during the pandemic. Therefore, chronic illness projections and comparisons to previous years may provide unrealistic and unfair results. It's likely that for chronic disease statistics, the COVID-19 period should be assessed only within, not with other periods. Although this pandemic has brought about enormous challenges for cardiovascular research, COVID-19 has also created many potential unique investigational opportunities for the cardiac anesthesiologists. A few of the discovery potential subjects are: 1. Long-term cardiovascular effects of COVID-19 -serial echocardiographic assessments in recovery-based intervals. 2. Long-term pulmonary effects of COVID-19. In conclusion, the unprecedented COVID-19 pandemic has dramatically impacted the scientific community and imposed significant impediments to scholarly inquiry. High quality, innovative, and adoptable discovery research in both cardiovascular and COVID-19 projects remain desperately needed. Anesthesiologists have a great The Impact of the COVID-19 Pandemic on Research Impact of the COVID-19 pandemic on clinical research COVID 19 and Clinical Trials: The Medidata Perspective FDA Guidance on Conduct of Clinical Trials of Medical Products During COVID-19 Public Health Emergency Guidance for NIH funded Clinical Trials and Human Subjects Studies Affected by COVID-19 The ethics of COVID-19 treatment studies: too many are open, too few are double-masked. The Centre for Evidence-Based Medicine RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19 Retracted coronavirus (COVID-19) papers. Retraction Watch Population trends in rates of percutaneous coronary revascularization for acute coronary syndromes associated with the COVID-19 outbreak Reduction in ST-segment elevation cardiac catheterization laboratory activations in the United States during COVID-19 pandemic Reductions in heart failure hospitalizations during the COVID-19 pandemic Same-Day Consent for Regional Anesthesia Clinical Research Trials: It's About Time Accuracy and usability of a self-administered 6-minute walk test smartphone application Association of implantable device measured physical activity with hospitalization for heart failure Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19) Conduct of Clinical Trials in the Era of COVID-19: JACC Scientific Expert Panel Myocardial localization of coronavirus in COVID-19 cardiogenic shock The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2 Continuing Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on Days Alive and Out of the Hospital in Patients Admitted With COVID-19: A Randomized Clinical Trial opportunity to be at the frontline of these efforts in providing safe patient care and solution generating clinical research.